Altimmune reports Q2 2026 results as pemvidutide advances in MASH, AUD and ALD

Altimmune announced second quarter 2026 financial results and a pipeline update on August 12, 2026, covering progress across its three liver disease programs for pemvidutide. Altimmune is a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases.¹

In MASH, the company announced in August 2026 the initiation of a global Phase 3 trial called "PERFORMA," with a 52-week data readout anticipated in 2029.¹ The trial is designed as a Phase 3, global, randomized, double-blind, placebo-controlled, parallel-group study evaluating efficacy, safety and clinical outcomes of pemvidutide in subjects with MASH.¹ This follows earlier news that pemvidutide was granted Breakthrough Therapy Designation by the FDA based on 24-week data from the IMPACT Phase 2b trial.¹

For alcohol use disorder, the company reported positive topline results in July 2026 from the RECLAIM Phase 2 trial, which tested pemvidutide against placebo in 100 patients over 24 weeks.¹ The trial met its primary endpoint of a statistically significant and clinically meaningful reduction in heavy drinking days, the company said, and also met secondary endpoints including a 2-level reduction in WHO-risk drinking levels and zero heavy drinking days, both described as endpoints the FDA recognizes for registration.¹ Altimmune said it plans to request an End-of-Phase 2 meeting with the FDA and to engage European regulators on next steps.¹

In alcohol-associated liver disease, the company completed enrollment in July 2026 for the RESTORE Phase 2 trial, a 48-week study comparing pemvidutide to placebo in about 120 patients.¹ The protocol was amended so the primary endpoint, change in Liver Stiffness Measurement, will be assessed first at Week 48 and then at Week 24, with topline data expected in the second half of 2027.¹

On finances, Altimmune held $519 million in cash, cash equivalents and investments as of June 30, 2026,¹ following an oversubscribed public offering in April 2026 that raised $225.0 million in gross proceeds.¹ The company also said in June 2026 it plans to relocate its headquarters to Morristown, New Jersey, later in the year.¹